However, iNOS can be overexpressed in a variety of pathological conditions that result in uncontrolled NO production, including inflammatory bowel disease, rheumatoid arthritis, and cancer; thus, iNOS inhibition could be a therapeutic strategy for these diseases (Cinelli et al., 2020; Maccallini et al., 2020). The gene discussed is NOS2; the disease is rheumatoid arthritis.